Gastroenterology

Fendrick explains how stool-based colorectal cancer screening tests can help alleviate the current colonoscopy backlog amid growing demand for the procedure.

A diagnosis of chronic kidney disease was approximately 3-times more likely in Crohn's disease than in ulcerative colitis.

Fendrick explains the value of additional modalities for colorectal cancer screening to combat the colonoscopy backlog and help patients get screened.

A retrospective analysis in the US found bariatric surgery lowers mortality rates and shortens hospital stays in patients admitted with NAFLD.

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

Initial consultations by female gastroenterologists led to a significant reduction in subsequent healthcare utilization compared with male gastroenterologists.

A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.

Geneoscopy's ColoSense received FDA approval on May 06, 2024 based on data from the phase 3 CRC-PREVENT trial.

This April 2024 month in review highlights World IBS Day, updates in the gastroenterology pipeline, ACP Internal Medicine meeting coverage, and recent IBD research.

Announced on April 18, the approval is based on the VISIBLE 2 trial and comes less than 7 months after the approval of SC vedolizumab in ulcerative colitis.

Wilt discusses the different screening methods recommended by ACP and explains how he talks about screening with his patients.

Wilt discusses ACP guidelines regarding what age to begin colorectal cancer screening and the benefits versus harms of screening at 45 compared to 50 years of age.

Experts discuss the warnings regarding IL-17 blockers and inflammatory bowel disease.

In recognition of World IBS Day, we spoke with Jeffrey Roberts about what led him to found the holiday in 2019 and took a closer look at the continued marginalization of the condition.

A new study found an intervention targeting proton pump inhibitor overuse was linked to an absolute reduction of 7.3%.

Incident use of anti-TNF therapy was linked to an increased risk of kidney function decline but not all-cause mortality in patients with newly diagnosed IBD.

Patients with a delayed appendicitis diagnosis had 1.23 times increased hospital care costs, and Black patients had a greater increased cost than White patients.

Findings demonstrate a similar postoperative safety profile for both tofacitinib and biologics in patients with medically refractory ulcerative colitis undergoing colectomy.

Findings highlight the safety and efficacy of switching from originator to biosimilar adalimumab, which also showed favorable results in adalimumab-naïve patients with IBD.

Findings highlight the negative impact of bowel urgency and bowel urgency-related accidents on the daily lives of patients with UC and CD.

In part 5 of our 5-part discussion, experts discuss their perspective on appropriate guidance for screening age and the future of CRC advocacy.

In part 4 of our 5-part discussion, experts discuss how to navigate conversations about risk factors and symptoms surrounding CRC.

In part 3 of our 5-part discussion, experts discuss the importance of screening among younger patient populations and strategies to encourage screening in patient populations susceptible to nonadherence.

In part 2 of our 5-part discussion, experts discuss challenges they face getting patients to engage in screening and how to effectively discuss screening with patients.

In part 1 of our 5-part discussion, experts discuss recent screening recommendation updates and the advent of new screening modalities.